{"id":"W2042737626","doi":"10.1016/j.msard.2013.10.006","title":"Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study","year":2013,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; London Health Sciences Centre; Western University","funders":"Novartis Pharma; EMD Serono; Genentech; Daiichi Sankyo Europe; Sanofi; European Commission; Glenmark Pharmaceuticals; Eli Lilly and Company; CSL Behring; Novartis Pharmaceuticals Corporation; Biogen; Novo Nordisk; Teva Pharmaceutical Industries; National Research Foundation; Universitätsspital Basel","keywords":"Fingolimod; Medicine; Glatiramer acetate; Discontinuation; Placebo; Adverse effect; Multiple sclerosis; Internal medicine; Disease; Immunology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01574005,0.0008245261,0.003659394,0.0008732579,0.0003250089,0.00127185,0.0007782503,0.0008349546,0.001706886],"category_scores_gemma":[0.01396106,0.0003137929,0.01278814,0.0008953209,0.0003509684,0.0006224829,0.0006761077,0.001226714,0.000115107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005171492,"about_ca_system_score_gemma":0.0008413302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001138977,"about_ca_topic_score_gemma":0.001943383,"domain_scores_codex":[0.9867347,0.007989095,0.001489554,0.001482015,0.001570639,0.0007339704],"domain_scores_gemma":[0.9864377,0.009043172,0.001976592,0.00155615,0.0004772043,0.0005091868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3719629,0.0007015471,0.4260644,0.001126604,0.1540438,0.0006462413,0.0005654422,0.002208504,0.005520804,0.0002432379,0.001860281,0.0350561],"study_design_scores_gemma":[0.01423673,0.02062329,0.8933254,0.0001370712,0.06122542,0.0005248957,0.0004714313,0.003813397,0.002240207,0.0007292989,0.002558361,0.0001144402],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916273,0.005102174,0.0007387988,0.0001614138,0.0001206299,0.0002184789,0.001339881,0.00002124129,0.0006701244],"genre_scores_gemma":[0.9976641,0.0003027058,0.0002833203,0.00009154493,0.00007682267,0.000175294,0.001144639,0.00001665642,0.0002448905],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01574005,"threshold_uncertainty_score":0.08324236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0934681497190447,"score_gpt":0.349094815101173,"score_spread":0.2556266653821283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}